Hanmi focuses on developing anticancer drugs for the discovery of new chemical entities. The typical pipeline of targeted anticancer is a pan-Her inhibitor, HM781-36B, which inhibits Her-1, Her-2, and Her-4 including EGFR mutants effectively. In addition, Hanmi discovered a novel P-glycoprotein inhibitor, HM30181A, which enables the new development of orally available drugs such as Oraxol and Oratecan.
45 Bangi-dong. Songpa. Seoul 138-724 Korea Tel 82. 2. 410. 9114
Copyright (c) 2004 by Hanmi Pharm Co Ltd. All rights reserved